Monika Anand

1.3k total citations
43 papers, 561 citations indexed

About

Monika Anand is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Oncology. According to data from OpenAlex, Monika Anand has authored 43 papers receiving a total of 561 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Pulmonary and Respiratory Medicine, 13 papers in Cancer Research and 11 papers in Oncology. Recurrent topics in Monika Anand's work include Prostate Cancer Treatment and Research (28 papers), Radiopharmaceutical Chemistry and Applications (10 papers) and Prostate Cancer Diagnosis and Treatment (7 papers). Monika Anand is often cited by papers focused on Prostate Cancer Treatment and Research (28 papers), Radiopharmaceutical Chemistry and Applications (10 papers) and Prostate Cancer Diagnosis and Treatment (7 papers). Monika Anand collaborates with scholars based in United States, India and United Kingdom. Monika Anand's co-authors include Silvia C. Finnemann, Emeline F. Nandrot, Dean Sheppard, Kamran Atabai, Dena Almeida, Andrew J. Armstrong, Daniel J. George, Susan Halabi, Patrick Healy and Michael R. Harrison and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Clinical Cancer Research.

In The Last Decade

Monika Anand

38 papers receiving 551 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Monika Anand United States 13 225 187 153 135 101 43 561
Anita S. Bowman United States 11 308 1.4× 210 1.1× 58 0.4× 114 0.8× 145 1.4× 22 612
Bhavani S. Kowtharapu Germany 15 368 1.6× 46 0.2× 76 0.5× 153 1.1× 63 0.6× 27 684
Gaia Barisione Italy 12 268 1.2× 59 0.3× 452 3.0× 294 2.2× 214 2.1× 16 808
Matthew Lovatt Singapore 17 350 1.6× 58 0.3× 512 3.3× 157 1.2× 49 0.5× 20 964
S. Maloney Canada 12 193 0.9× 51 0.3× 114 0.7× 114 0.8× 343 3.4× 32 528
Oleg V. Grinchuk Singapore 12 392 1.7× 97 0.5× 51 0.3× 55 0.4× 98 1.0× 15 559
Nancy J. Nesslinger Canada 10 305 1.4× 141 0.8× 482 3.2× 521 3.9× 57 0.6× 12 943
Zhaodong Zhong China 13 430 1.9× 33 0.2× 153 1.0× 247 1.8× 33 0.3× 49 800
Qiang Zheng China 11 303 1.3× 39 0.2× 43 0.3× 42 0.3× 65 0.6× 22 602
Brian Labadie United States 12 284 1.3× 121 0.6× 344 2.2× 380 2.8× 49 0.5× 24 769

Countries citing papers authored by Monika Anand

Since Specialization
Citations

This map shows the geographic impact of Monika Anand's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Monika Anand with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Monika Anand more than expected).

Fields of papers citing papers by Monika Anand

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Monika Anand. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Monika Anand. The network helps show where Monika Anand may publish in the future.

Co-authorship network of co-authors of Monika Anand

This figure shows the co-authorship network connecting the top 25 collaborators of Monika Anand. A scholar is included among the top collaborators of Monika Anand based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Monika Anand. Monika Anand is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Anand, Monika, et al.. (2025). Secure Byzantine Fault Tolerance Mechanisms for Quantum Computing. 912–917.
2.
Anand, Monika, et al.. (2024). Implementation of Cryptographic Algorithm for Cloud Data Security. 1–7. 2 indexed citations
5.
Koontz, Bridget F., Karen E. Hoffman, Susan Halabi, et al.. (2024). Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer. Prostate Cancer and Prostatic Diseases. 28(2). 503–505.
6.
8.
Brown, Landon C., Susan Halabi, Jason A. Somarelli, et al.. (2022). A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer. Prostate Cancer and Prostatic Diseases. 25(4). 762–769. 26 indexed citations
9.
Zhang, Jiaren, Giuseppe Galletti, Susan Halabi, et al.. (2022). Association of circulating tumor cell RB1 loss RNA signature with outcomes and immune phenotypes in men with mCRPC.. Journal of Clinical Oncology. 40(6_suppl). 139–139.
10.
Gupta, Santosh, Susan Halabi, Gabor Kemeny, et al.. (2021). Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer. Molecular Cancer Research. 19(6). 1040–1050. 19 indexed citations
11.
Zhang, Tian, Anika Agarwal, Rengasamy Boominathan, et al.. (2021). Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer. Biomarker Research. 9(1). 14–14. 31 indexed citations
12.
Bitting, Rhonda L., Patrick Healy, Daniel J. George, et al.. (2020). Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial. European Urology Oncology. 4(6). 948–954. 23 indexed citations
13.
14.
George, Daniel J., Susan Halabi, Patrick Healy, et al.. (2019). Phase 2 clinical trial of TORC1 inhibition with everolimus in men with metastatic castration-resistant prostate cancer. Urologic Oncology Seminars and Original Investigations. 38(3). 79.e15–79.e22. 23 indexed citations
15.
Holl, Eda K., Megan McNamara, Patrick Healy, et al.. (2019). Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients. Prostate Cancer and Prostatic Diseases. 22(4). 588–592. 17 indexed citations
16.
Harrison, Michael R., Paul G. Davis, Rajan T. Gupta, et al.. (2018). EXTEND: Safety and efficacy of exercise training in men receiving enzalutamide (ENZ) in combination with conventional androgen deprivation therapy (ADT) for hormone naïve prostate cancer (HSPC). Annals of Oncology. 29. viii623–viii624. 1 indexed citations
17.
Anand, Sanjeev & Monika Anand. (2017). Smart Cities: Environmental Challenges and Green Computing. International Journal of Advanced Research in Computer Science. 8(4). 3 indexed citations
18.
Armstrong, Andrew J., Susan Halabi, Patrick Healy, et al.. (2016). A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy. Prostate Cancer and Prostatic Diseases. 19(1). 100–106. 13 indexed citations
19.
Medina, Daniel, Mecide Gharibo, Philip Savage, et al.. (2008). A Pilot study of allogeneic cellular therapy for patients with advanced hematologic malignancies. Leukemia Research. 32(12). 1842–1848. 12 indexed citations
20.
Nandrot, Emeline F., et al.. (2005). Novel role for αvβ5-integrin in retinal adhesion and its diurnal peak. American Journal of Physiology-Cell Physiology. 290(4). C1256–C1262. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026